Limits...
Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Bützow R, Zipfel PF, Meri S - Br. J. Cancer (2002)

Bottom Line: We observed that the soluble complement regulators factor H and factor H-like protein were abundantly present in ascites samples as well as in primary tumours of patients with ovarian cancer.In ascites samples the mean level of factor H-like protein (130+/-55 microg ml(-1)) was 5.5-fold higher than in normal human serum (24+/-3 microg ml(-1)).Subsequently, the PA-1 and SW626 cell lines were found to secrete a soluble form of the membrane cofactor protein (CD46).

View Article: PubMed Central - PubMed

Affiliation: Department of Bacteriology and Immunology, Haartman Institute, University Central Hospital, FIN-0014 Helsinki, Finland.

Show MeSH

Related in: MedlinePlus

Immunohistochemical analysis of the presence of FHL-1 and factor H in ovarian tumours. Cryostat sections (5 μm) of a serous cystadenocarcinoma were fixed and stained with the 196X (A, B) and VIG8 (C, D) mAb against factor H/FHL-1 SCR1 and factor H SCR19-20, respectively. MCP expression was analysed by the mouse anti-MCP mAb BG24 (E, F) and an irrelevant mouse IgG was used as a negative control (G, H). The bound mAbs were detected using the Vectastain ABC immunoperoxidase staining kit. Original magnifications, 200× (left row) and 400× (right row). While combined staining for factor H and FHL-1 occurred throughout the tumour epithelium (A, B) positive staining for factor H (C, D) was seen most strongly on the outermost mucus layer. Arrows indicate positively stained areas.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376183&req=5

fig2: Immunohistochemical analysis of the presence of FHL-1 and factor H in ovarian tumours. Cryostat sections (5 μm) of a serous cystadenocarcinoma were fixed and stained with the 196X (A, B) and VIG8 (C, D) mAb against factor H/FHL-1 SCR1 and factor H SCR19-20, respectively. MCP expression was analysed by the mouse anti-MCP mAb BG24 (E, F) and an irrelevant mouse IgG was used as a negative control (G, H). The bound mAbs were detected using the Vectastain ABC immunoperoxidase staining kit. Original magnifications, 200× (left row) and 400× (right row). While combined staining for factor H and FHL-1 occurred throughout the tumour epithelium (A, B) positive staining for factor H (C, D) was seen most strongly on the outermost mucus layer. Arrows indicate positively stained areas.

Mentions: To investigate the presence of FHL-1 and factor H in ovarian tumours in vivo, we analysed cryostat sections of serous ovarian tumours with the VIG8 (detects SCR19-20 of factor H) and 196X (detects SCR1 of factor H and FHL-1) mAbs and immunoperoxidase staining. Examples of the stainings are shown in Figure 2Figure 2


Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Bützow R, Zipfel PF, Meri S - Br. J. Cancer (2002)

Immunohistochemical analysis of the presence of FHL-1 and factor H in ovarian tumours. Cryostat sections (5 μm) of a serous cystadenocarcinoma were fixed and stained with the 196X (A, B) and VIG8 (C, D) mAb against factor H/FHL-1 SCR1 and factor H SCR19-20, respectively. MCP expression was analysed by the mouse anti-MCP mAb BG24 (E, F) and an irrelevant mouse IgG was used as a negative control (G, H). The bound mAbs were detected using the Vectastain ABC immunoperoxidase staining kit. Original magnifications, 200× (left row) and 400× (right row). While combined staining for factor H and FHL-1 occurred throughout the tumour epithelium (A, B) positive staining for factor H (C, D) was seen most strongly on the outermost mucus layer. Arrows indicate positively stained areas.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376183&req=5

fig2: Immunohistochemical analysis of the presence of FHL-1 and factor H in ovarian tumours. Cryostat sections (5 μm) of a serous cystadenocarcinoma were fixed and stained with the 196X (A, B) and VIG8 (C, D) mAb against factor H/FHL-1 SCR1 and factor H SCR19-20, respectively. MCP expression was analysed by the mouse anti-MCP mAb BG24 (E, F) and an irrelevant mouse IgG was used as a negative control (G, H). The bound mAbs were detected using the Vectastain ABC immunoperoxidase staining kit. Original magnifications, 200× (left row) and 400× (right row). While combined staining for factor H and FHL-1 occurred throughout the tumour epithelium (A, B) positive staining for factor H (C, D) was seen most strongly on the outermost mucus layer. Arrows indicate positively stained areas.
Mentions: To investigate the presence of FHL-1 and factor H in ovarian tumours in vivo, we analysed cryostat sections of serous ovarian tumours with the VIG8 (detects SCR19-20 of factor H) and 196X (detects SCR1 of factor H and FHL-1) mAbs and immunoperoxidase staining. Examples of the stainings are shown in Figure 2Figure 2

Bottom Line: We observed that the soluble complement regulators factor H and factor H-like protein were abundantly present in ascites samples as well as in primary tumours of patients with ovarian cancer.In ascites samples the mean level of factor H-like protein (130+/-55 microg ml(-1)) was 5.5-fold higher than in normal human serum (24+/-3 microg ml(-1)).Subsequently, the PA-1 and SW626 cell lines were found to secrete a soluble form of the membrane cofactor protein (CD46).

View Article: PubMed Central - PubMed

Affiliation: Department of Bacteriology and Immunology, Haartman Institute, University Central Hospital, FIN-0014 Helsinki, Finland.

Show MeSH
Related in: MedlinePlus